Subscribe To
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-00...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-00...
November 3, 2023, 8:30 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...
November 3, 2023, 10:00 am
Should you still buy the nasdaq's best-performing october stocks?
Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that...
November 3, 2023, 5:20 am
Poolbeg's lead asset to be in the spotlight at leading medical conference
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste...
November 3, 2023, 3:32 am
Pipeline moves: approval prospects rise for oesophageal cancer drug after trial completion
On a good note, we investigate the completion of a Phase IIb trial in congestive heart failure and chronic kidney disease, a Phase II trial in triple-...
November 2, 2023, 8:29 pm
Experts are seeing more cancer in younger adults: aflac ceo
Aflac CEO Dan Amos discusses the insurance company's strong Q3 earnings report and addresses rising health costs on 'The Claman Countdown.' #foxbusine...
November 2, 2023, 7:00 pm
Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc
– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – SAN DIE...
November 2, 2023, 11:30 am
Lucid diagnostics to present at canaccord genuity medtech, diagnostics, and digital health & services forum
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq...
November 2, 2023, 9:18 am
Vincerx pharma to present three posters at ash 2023 in december
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favora...
November 2, 2023, 9:10 am
Olema oncology to participate in upcoming investor conferences in november
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biop...
November 1, 2023, 8:27 pm
Siren biotechnology awarded $4m in grant funding from the california institute for regenerative medicine (cirm)
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Siren Biotechnology, a gene therapy company pioneering Universal AAV Immuno-Gene Therapies for ...
November 1, 2023, 4:46 pm
Olema oncology to participate in upcoming investor conferences in november
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage bioph...
November 1, 2023, 4:27 pm
Gracell biotechnologies to participate in four upcoming investor conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA...
November 1, 2023, 4:00 pm
Seagen 3q revenue beat driven by jump in product sales
Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimat...
November 1, 2023, 12:11 pm